Boston Scientific Continues Acquisition Streak With $1.75Bn Deal For Baylis’ Cardiology Products
The deal includes Baylis’ NRG and VersaCross transseptal access platforms which complement Boston Scientific’s catheter-based devices that require left-heart access.
You may also be interested in...
Exec Chat: PFA, Patient Monitoring, Modular CRM Open Opportunities For Boston Scientific
In an interview with Medtech Insight, Angelo De Rosa, the general manager of Boston Scientific’s cardiac rhythm management and electrophysiology businesses in Europe, Middle East and Africa (EMEA), discussed some of his company’s recent achievements and the opportunities it is addressing in 2022.
JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.
Boston Scientific Acquires Devoro Medical To Add Thrombectomy Tech
Boston Scientific will pay $269m for the 84% of Devoro that it does not already own and up to $67m upon achievement of certain clinical and regulatory milestones.